Phase 3 PTSD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children aged from 44 weeks post-menstrual age (a measure used for premature babies) up to 11 years old (confirm with trial site if unsure how age is calculated)
- Children who are planned to be admitted to the pediatric ICU at Monroe Carell Jr. Children's Hospital at Vanderbilt
- Children who need a breathing machine (mechanical ventilator) and sedation medication to keep them calm and comfortable
Who may not be able to join:
- Children who have already been on continuous sedation for more than 72 hours before being assessed for the trial
- Children whose breathing problems are clearing up quickly and who are expected to be taken off the breathing machine very soon
- Children who had significant pre-existing cognitive or developmental disability before their current illness, based on a specific medical rating scale (confirm with trial site)
- Children with certain serious heart rhythm problems or a heart rate below 60 beats per minute
- Children who are medically dependent on a continuous drip of benzodiazepine (a type of sedation medication)
- Children who cannot be enrolled alongside another research study at the same time
- Children who are expected to pass away or have a plan to stop life-sustaining treatment within 24 hours of joining
- Children with total vision loss in both eyes
- Children with deafness that would prevent doctors from being able to assess them for delirium (a state of confusion)
- Children who cannot understand English well enough for delirium testing to be completed — though this may not apply if research staff or translation services are available in the child's language (confirm with trial site)
- Children with a documented allergy to either of the two study medications: dexmedetomidine or midazolam
- Children who are expected to need continuous muscle-paralysing medication (neuromuscular blockade) for at least 48 hours at the time of assessment
- Children whose weight at the time of assessment is above 50 kilograms
- Cases where the consent process cannot be started within 72 hours of the child first meeting all the eligibility requirements — for example, if the child's legal guardian is unavailable, declines, or does not speak a language that available staff or translators can support
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Heidi Smith, MD, MSCI, Vanderbilt University Medical Center
Phone: (615) 936-6808
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Daily prevalence of delirium
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.